Page 70 - Read Online

6. van Lingen AV, Arends TJ, Witjes JA. Expert review: an Lymphatics, lymph nodes and the immune system: barriers
update in current and developing intravesical therapies for and gateways for cancer spread. Clin Exp Metastasis
non-muscle-invasive bladder cancer. Expert Rev Anticancer 2012;29:729-36.
Ther 2013;13:1257-68. 25. Pereira ER, Jones D, Jung K, Padera TP. The lymph node
7. Zagouri F, Peroukidis S, Tzannis K, Kouloulias V, Bamias A, microenvironment and its role in the progression of metastatic
Hellenic Genito-Urinary Cancer Group (HCUCG). Current cancer. Semin Cell Dev Biol 2015;38:98-105.
clinical practice guidelines on chemotherapy and radiotherapy 26. Seyfried TN, Huysentruyt LC. On the origin of cancer
for the treatment of non-metastatic muscle-invasive urothelial metastasis. Crit Rev Oncog 2013;18:43-73.
cancer: a systematic review and critical evaluation by the 27. Holopainen T, Bry M, Alitalo K, Saaristo A. Perspectives on
Hellenic Genito-Urinary Cancer Group (HGUCG). Crit Rev lymphangiogenesis and angiogenesis in cancer. J Surg Oncol
Oncol Hematol 2015;93:36-49. 2011;103:484-8.
8. Knowles MA, Hurst CD. Molecular biology of bladder cancer: 28. Cao Z, Shang B, Zhang G, Miele L, Sarkar FH, Wang Z,
new insights into pathogenesis and clinical diversity. Nat Rev Zhou Q. Tumor cell-mediated neovascularization and
Cancer 2014;15:25-41. lymphangiogenesis contrive tumor progression and cancer
9. Cheung G, Sahai A, Billia M, Dasgupta P, Khan MS. Recent metastasis. Biochim Biophys Acta 2013;1836:273-86.
advances in the diagnosis and treatment of bladder cancer. 29. Shibata MA, Morimoto J, Shibata E, Otsuki Y. Combination
BMC Med 2013;11:13. therapy with short interfering RNA vectors against VEGF-C
10. Yeung C, Dinh T, Lee J. The health economics of bladder and VEGF-A suppresses lymph node and lung metastasis in
cancer: an updated review of the published literature. a mouse immunocompetent mammary cancer model. Cancer
Pharmacoeconomics 2014;32:1093-104. Gene Ther 2008;15:776-86.
11. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, 30. Zhang D, Li B, Shi J, Zhao L, Zhang X, Wang C, Hou S,
Comperat E, Sylvester RJ, Kaasinen E, Bohle A, Qian W, Kou G, Wang H, Guo Y. Suppression of tumor
Palou Redorta J, Roupret M, European Association of Urology. growth and metastasis by simultaneously blocking vascular
EAU guidelines on non-muscle-invasive urothelial carcinoma endothelial growth factor (VEGF)-A and VEGF-C with
of the bladder: Update 2013. Eur Urol 2013;64:639-53. a receptor-immunoglobulin fusion protein. Cancer Res
12. Witjes JA, Comperat E, Cowan NC, De Santis M, Gakis G, 2010;70:2495-503.
Lebret T, Ribal MJ, Van der Heijden AG, Sherif A, European 31. Eklund L, Bry M, Alitalo K. Mouse models for studying
Association of Urology. EAU guidelines on muscle-invasive angiogenesis and lymphangiogenesis in cancer. Mol Oncol
and metastatic bladder cancer: summary of the 2013 2013;7:259-82.
guidelines. Eur Urol 2014;65:778-92. 32. Gacche RN, Meshram RJ. Angiogenic factors as potential
13. Birkhahn M, Mitra AP, Williams AJ, Lam G, Ye W, Datar RH, drug target: effi cacy and limitations of anti-angiogenic therapy.
Balic M, Groshen S, Steven KE, Cote RJ. Predicting Biochim Biophys Acta 2014;1846:161-79.
recurrence and progression of noninvasive papillary bladder 33. Kim S, Ding W, Zhang L, Tian W, Chen S. Clinical response
cancer at initial presentation based on quantitative gene to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI)
expression profi les. Eur Urol 2010;57:12-20. in solid cancers: a review of clinical trials. Onco Targets Ther
14. van Rhijn BW. Combining molecular and pathologic data to 2014;7:719-28.
prognosticate non-muscle-invasive bladder cancer. Urol Oncol 34. Welti J, Loges S, Dimmeler S, Carmeliet P. Recent molecular
2012;30:518-23. discoveries in angiogenesis and antiangiogenic therapies in
15. Ru Y, Dancik GM, Theodorescu D. Biomarkers for prognosis cancer. J Clin Invest 2013;123:3190-200.
and treatment selection in advanced bladder cancer patients. 35. Maione F, Giraudo E. Tumor angiogenesis: methods to analyze
Curr Opin Urol 2011;21:420-7. tumor vasculature and vessel normalization in mouse models
16. Fuzery AK, Levin J, Chan MM, Chan DW. Translation of of cancer. Methods Mol Biol 2015;1267:349-65.
proteomic biomarkers into FDA approved cancer diagnostics: 36. Pignot G, Bieche I, Vacher S, Guet C, Vieillefond A, Debre B,
issues and challenges. Clin Proteomics 2013;10:13. Lidereau R, Amsellem-Ouazana D. Large-scale real-time
17. Ye F, Wang L, Castillo-Martin M, McBride R, Galsky MD, reverse transcription-PCR approach of angiogenic pathways in
Zhu J, Boffetta P, Zhang DY, Cordon-Cardo C. Biomarkers human transitional cell carcinoma of the bladder: identifi cation
for bladder cancer management: present and future. Am J Clin of VEGFA as a major independent prognostic marker. Eur
Exp Urol 2014;2:1-14. Urol 2009;56:678-88.
18. Miremami J, Kyprianou N. The promise of novel molecular 37. Santos L, Costa C, Pereira S, Koch M, Amaro T, Cardoso F,
markers in bladder cancer. Int J Mol Sci 2014;15:23897-908. Guimaraes T, Bento MJ, Lobo F, Pinto S, Lopes C.
19. Buti S, Ciccarese C, Zanoni D, Santoni M, Modena A, Neovascularisation is a prognostic factor of early recurrence in
Maines F, Gilli A, Bria E, Brunelli M, Rimanti A, Cascinu S, T1/G2 urothelial bladder tumours. Ann Oncol 2003;14:1419-24.
Ardizzoni A, Tortora G, Massari F. Prognostic and predictive 38. Canoglu A, Gogus C, Beduk Y, Orhan D, Tulunay O,
factors in patients treated with chemotherapy for advanced Baltaci S. Microvessel density as a prognostic marker in
urothelial cancer: where do we stand? Future Oncol bladder carcinoma: correlation with tumor grade, stage and
2015;11:107-19. prognosis. Int Urol Nephrol 2004;36:401-5.
20. Soloway MS. Bladder cancer: Lack of progress in bladder 39. Fauconnet S, Bernardini S, Lascombe I, Boiteux G, Clairotte A,
cancer -what are the obstacles? Nat Rev Urol 2013;10:5-6. Monnien F, Chabannes E, Bittard H. Expression analysis of
21. Hanahan D, Weinberg RA. Hallmarks of cancer: the next VEGF-A and VEGF-B: relationship with clinicopathological
generation. Cell 2011;144:646-74. parameters in bladder cancer. Oncol Rep 2009;21:1495-504.
22. Mendoza M, Khanna C. Revisiting the seed and soil in cancer 40. Afonso J, Santos LL, Longatto-Filho A. Bladder
metastasis. Int J Biochem Cell Biol 2009;41:1452-62. cancer - From basic science to robotic surgery. In: Canda A,
23. Leber MF, Efferth T. Molecular principles of cancer invasion editor. Angiogenesis, Lymphangiogenesis and Lymphovascular
and metastasis (review). Int J Oncol 2009;34:881-95. Invasion: Prognostic Impact for Bladder Cancer Patients.
24. Ferris RL, Lotze MT, Leong SP, Hoon DS, Morton DL. Croatia: INTECH; 2012. p. 87-116.

Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 2 ¦ July 15, 2015 ¦ 63